The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the positive opinion  VIVID-1 was the first pivotal Cro...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker is gaining ground on its Eu...

Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as both a combination and monotherapy.

Eli Lilly (LLY -0.44%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings.

As monotherapy, imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations As combination therapy, imlune...

Eli Lilly CEO David Ricks on Tuesday said at the Economic Club of Washington that tax and regulation reform and drug affordability were some policy focuses for the company in a second Trump adminis...

Late on December 9, the former hedge fund manager and energetic host of Mad Money, Jim Cramer, took to X to share his two cents on which sectors in the stock market are overrepresented and which ar...

INDIANAPOLIS , Dec. 9, 2024 /PRNewswire/ -- Today, the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion sh...

Growth. It's what most investors want more than anything else from their stocks. Some stocks can deliver more of it than others.

Eli Lilly (LLY 0.13%) has produced a wide variety of treatments for various illnesses throughout its 145-year history. But this big pharma company truly took center stage over the past year or so, ...

The latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications.

Eli Lilly and Co (NYSE:LLY) has announced a $3 billion expansion of its manufacturing plant in Kenosha County, Wisconsin, driven by increasing demand for GLP-1 receptor agonists such as the company...

Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it means for Eli Lilly's future growth.

Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its wei...

Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health ...